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Abstract
Objectives To evaluate multiparametric-MRI (mpMRI) de-
rived histogram textural-analysis parameters for detection of
transition zone (TZ) prostatic tumour.
Methods Sixty-seven consecutive men with suspected prostate
cancer underwent 1.5T mpMRI prior to template-mapping-
biopsy (TPM). Twenty-six men had ‘significant’ TZ tumour.
Two radiologists in consensus matched TPM to the single axial
slice best depicting tumour, or largest TZ diameter for those with
benign histology, to define single-slice whole TZ-regions-of-
interest (ROIs). Textural-parameter differences between single-
slice whole TZ-ROI containing significant tumour versus
benign/insignificant tumour were analysed using Mann
Whitney U test. Diagnostic accuracy was assessed by receiver
operating characteristic area under curve (ROC-AUC) analysis
cross-validated with leave-one-out (LOO) analysis.
Results ADC kurtosis was significantly lower (p < 0.001) in
TZ containing significant tumour with ROC-AUC 0.80
(LOO-AUC 0.78); the difference became non-significant fol-
lowing exclusion of significant tumour from single-slice
whole TZ-ROI (p = 0.23). T1-entropy was significantly lower
(p = 0.004) in TZ containing significant tumour with ROC-
AUC 0.70 (LOO-AUC 0.66) and was unaffected by excluding
significant tumour from TZ-ROI (p = 0.004). Combining
these parameters yielded ROC-AUC 0.86 (LOO-AUC 0.83).
Conclusion Textural features of the whole prostate TZ can
discriminate significant prostatic cancer through reduced kur-
tosis of the ADC-histogram where significant tumour is in-
cluded in TZ-ROI and reduced T1 entropy independent of
tumour inclusion.
Key Points
•MR textural features of prostate transition zone may discrim-
inate significant prostatic cancer.
• Transition zone (TZ) containing significant tumour demon-
strates a less peaked ADC histogram.
• TZ containing significant tumour reveals higher post-
contrast T1-weighted homogeneity.
• The utility of MR texture analysis in prostate cancer merits
further investigation.
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Introduction
Management of early prostate cancer has been revolutionised
by the use of multi-parametricMRI (mpMRI; using T2 and T1
weighted, diffusion-weighted and contrast- enhanced imag-
ing) [1]. Nonetheless, transition zone (TZ) tumours remain
more difficult to appreciate on mpMRI studies [2]; with re-
ported sensitivity/specificity for detection of 0.53/0.83 com-
pared with 0.80/0.97, respectively, for peripheral zone (PZ)
tumours [1]. TZ tumour signal homogeneity has been advo-
cated as a discriminator of significant grade disease at mpMRI
and has been incorporated into the recently revised ‘Pi-RADS
2’ guidelines [3]; endorsed by the European Society of
Urogenital Radiology and the American College of
Radiology.
Textural analysis is an image-processing technique that can
assess image signal heterogeneity (both at and beyond that
appreciated by the human eye) by quantifying the coarseness
and regularity of the spatial distribution of pixel grey level
values within normal and pathological tissue. Macroscopic
heterogeneity in medical images may reflect microscopic het-
erogeneity at the histopathological level, particularly in onco-
logical imaging with recent demonstrations of utility in tu-
mour detection/grading, prognosis and treatment response
[4, 5]. Compared to CT, MRI offers the advantages of im-
proved soft tissue contrast resolution and of a wealth of imag-
ing data afforded by a multi-parametric approach. Recent
studies have used MR textural analysis (MRTA) for lesion
detection, classification, treatment response-evaluation and
prediction for example in breast, brain, and rectal cancer
[6–8]. A number of approaches to texture analysis exist, with
one approach being quantification of features through histo-
gram analysis [9].
It is possible the additional tissue heterogeneity data pro-
vided by textural analysis could augment the diagnostic accu-
racy of radiologists in detecting TZ tumours, where lesions
tend to be subtle and difficult to differentiate from adjacent
benign nodular tissue. In this study, image analysis was per-
formed on a whole TZ basis with the aim of obviating the need
for radiological pre-identification of tumour, thus increasing
potential utility in computer-aided diagnosis (CAD) and to
minimise inherent difficulties of small lesion contouring.
The purpose of this study was to evaluate multiparametric
MRI (mpMRI) derived histogram textural analysis parameters
[9] for detection of transition zone (TZ) prostatic tumour.
Materials and methods
Our local institutional review board approved the study and
waived the requirement for individual consent for this retro-
spective study of consecutive patient data acquired as part of
routine clinical care (R&D No: 12/0195).
Patient cohort
The cohort comprised men with clinically suspected prostate
cancer undergoing prostatic mpMRI prior to ‘20 zone’ tem-
plate prostate mapping (TPM) biopsies (within 12 months)
between 1 January 2010 to 31 December 2012 (n = 210).
Men who had a peripheral zone tumour, undergone biopsy
within 6 months prior to mpMRI, received previous treatment
for prostate cancer, had metallic hip prostheses, or had incom-
plete mpMRI and/or TPM data sets were excluded (n = 143).
In total sixty-seven men with mean age 63.4 years (45–
80 years), mean PSA 9.2 ng/ml (0.2–39.0 ng/ml) and mean
gland volume of 42.9 ml (15–101 ml) were accrued. Of these
29/67 (43%) had no cancer, 26/67 (39%) had ‘significant’ TZ
cancer and 12/67 (18 %) had ‘insignificant’ TZ cancer (see
below). Table 1 summarizes cohort demographics.
Multi-parametric magnetic resonance imaging
Subjects underwent 1.5T magnet mpMRI (Avanto, Siemens,
Erlangen, Germany) with pelvic-phased array coil, following
intravenous spasmolytic (Buscopan; Boehringer Ingelheim,
Germany) 0.2 mg/kg (maximum 20 mg) to minimize bowel
peristalsis. Full mpMRI parameters are given in Table 2.
Figure 1 shows an example mpMRI with a significant TZ
tumour.
Transperineal template-prostate-mapping biopsy
TPM followedmpMRI with a median interval of 56 days (2 to
214 days); method as previously described [10, 11]. In brief,
systematic biopsy of the whole gland was performed through
a brachytherapy template-grid and 5-mm sampling frame, giv-
ing a uniform sampling density of approximately 1 core/cc of
prostatic tissue. Biopsies were grouped and potted into 20
zones, modified from the technique reported by Barzell et al.
[12].
Histopathology review
Subjects were grouped according to a previously used defini-
tion of cancer significance [13] whereby TPMmaximum can-
cer core length (MCCL) values were used to infer volume,
following demonstration that a TPM MCCL of ≥4 mm ap-
proximates to a tumour volume of ≥0.2 ml [14].
Clinically significant disease was defined as ≥Gleason 3 +
4 OR ≥4 mm MCCL, while other disease (i.e., ‘low risk’
<4 mm MCCL AND ≤Gleason 3 + 3) was classified as non-
significant and grouped with patients demonstrating benign
TZ histology [15].
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Histology-MRI Matching
Two radiologists in consensus (HSS, SP; with 8 years and
4 years of experience, respectively, for mpMRI interpretation),
aware of histopathological findings, reviewed each dataset
using Osirix (version 3.5.1; Geneva, Switzerland) and
matched the single axial slice depicting the TZ focus most
suspicious for disease to location of disease confirmed accord-
ing to histopathology. If no tumour was present, the radiolo-
gists selected the slice with the largest TZ anteroposterior
diameter. Where biopsy-positive significant tumour was pres-
ent, the radiologists also contoured significant tumours on
each ADC, T2 and T1 weighted TZ single slice image to
analyse the effect of initially including and then excluding
significant tumours from the single-slice whole TZROI drawn
by a third radiologist (below). TZ tumour contoured on T2
images was used for tumour area estimation (relative to total
TZ area).
A third radiologist (SB; with 2 years of experience for
mpMRI interpretation), blinded to biopsy data and earlier tu-
mour region of interest (ROI) placement, contoured solely the
entire TZ on the selected slice, on matched ADC, T2 and early
post-contrast T1 weighted images for each patient for subse-
quent MRTA.
The percentage of TZ replaced by tumour was quantified
by [(tumour area / TZ area)*100].
Table 2 Multi-parametricMRI
sequenceparametersusedforstudy;
*dynamic contrast enhancedMRI–
0.2ml/kg intravenous gadolinium
contrast agent injected at the
beginning of acquisition 6 at 3ml/s
followed by a saline flush of 20ml;
T2wTSE –T2weighted turbo spin
echo; EPI-DWI – echo planar
imaging - diffusionweighted
imaging; FLASH – fast low angle
shot. Note coronal T2 acquisition
was not used for image analysis
(though remains part of the clinical
scan). Apparent diffusion co-
efficient (ADC)map automatically
generated from the four b-values
(mono-exponential). ‘Early post
contrast T1’ image refers to the
second image temporally from the
point at which contrast first appears
in theprostate gland (imagingevery
16 seconds)
T2w TSE
axial/coronal
EPI DWI T1 3D FLASH*
Repetition time (ms) 5170 / 5240 2100 5.61
Echo time (ms) 92 / 104 98 2.5
Flip angle (degrees) 180 / 150 90 15
Echo train length 22 / 24 172 n/a
Bandwidth (Hz/Px) 190 / 190 968 300
Field of view (mm) 180 / 180 260 260
Phase FoV % 100 / 100 100 100
Slice thickness (mm) 3 / 3 5 3
Slice gap (mm) 0.3 / 0.3 0 0.6
Averages 2 / 2 16 1
Phase encoding direction A > P / R > L A > p A > P
Fat saturation No / No Yes Yes
Base matrix 256 / 256 172 192
Matrix phase % 95 / 95 100 100
b-values (s.mm-2) n/a 0, 300, 500, 1000 n/a
Number of acquisitions 1 / 1 1 35
Temporal resolution (s) n/a n/a 16
Total acquisition time (min) 3m54s / 4m18s 3m39s 10 m
Table 1 Summary of demographic and ROI areas for recruited patients
categorised by benign/insignificant transition (TZ) pathology and
significant TZ tumours (MCCL = maximum cancer core length,
G =Gleason grade, PSA = prostate specific antigen serum concentration,
TPM= template mapping biopsy)
Cancer significance Number (%) Mean Age
years
(range)
Mean PSA
ng/dL
(range)
Mean prostate
volume ml
(range)
Median time
interval mpMRI
to TPM days
(range)
Mean area TZ
ROI cm2
(Total; range)
Mean area
TZ tumour cm2
(Total; range)
Percentage TZ
tumour area/TZ
area (Total; range)
Benign OR 41 64 8.6 47.0 54 40.0 0.76 2.4
Insignificant
(<4 mm MCCL
AND ≤G3 + 3)
(61 %) 64 (45-79) (0.2-39) (20-101) (6-214) (n = 41;
10.0-68.9)
(n = 12;
0.52-1.22)
(n = 12;
1.1-3.7)
Significant 26 63 9.9 37.2 56 29.9 1.45 5.3
(≥4 mm MCCL
OR ≥G3 + 4)
(39 %) (52-80) (0.3-35) (15-78) (16-145) (n = 26;
9.3-61.2)
(n = 26;
0.65-3.80)
(n = 26;
1.7- 14.0)
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MRTextural Analysis (MRTA)
The ADC map, T2 and early post-contrast T1 weighted seg-
mented TZ regions from the selected slice (containing and
initially including tumour where present) underwent MRTA
(BG, with 9 years of experience in texture analysis) using
proprietary TexRAD research software (version 3.3,
TexRAD Ltd, Feedback Plc, Cambridge, UK) with automated
texture parameter extraction. A subsequent separate analysis
examined single-slice whole TZ ROIs excluding significant
tumours to assess the effect on textural parameters.
MRTA comprised image histogram analysis to quantify
first-order statistics of entropy, skewness, and kurtosis of the
TZ ROIs. These parameters reflect, to varying degrees, the
number, intensity and variability of areas of high and low
signal intensity within the TZ [9]. Absolute T2 and T1 weight-
ed signal intensities are not comparable across patients with-
out standardisation, and; therefore, T1 and T2 mean pixel,
mean positive pixel and standard deviation values were not
analysed further (unlike mean ADC). By contrast, measure-
ment of entropy, kurtosis and skewness rely on the shape of
the histogram, i.e., relationships between pixel intensities and
not on the absolute pixel intensity values.
Statistical Analysis
For each individual textural variable, the significance of dif-
ference between non-significant/benign TZ and significant tu-
mours containing TZwere assessed using the two tailedMann
Whitney U test (statistical significance assigned at p < 0.05).
These analyses were repeated after exclusion of significant
tumour area from the single-slice whole TZ ROI to determine
if the observed differences in textural parameters could be
directly attributed to inclusion of significant tumour within
the analyzed TZ ROI. Receiver-operating characteristics
(ROC) analyses characterised the performance of TZ textural
features extracted from each of ADC, T1 and T2 weighted TZ
ROI to predict significant TZ prostate cancer.
The area under the ROC curve (ROC AUC) and 95 %
confidence intervals for each parameter identified the best
performing individual parameters and in combination using
multivariate ROC-AUC analysis [16]. Leave-one-out (LOO)
analysis [17] validated classification performance for best
performing univariate and combined parameters.
All statistical analyses were performed using SPSS statis-
tics for Windows (version 16; IBM, Armonk, NY) and
MedCalc for Windows (version 9.2.0.0; MedCalc software,
Mariakerke, Belgium).
Results
Patient cohort
Mean tumour area was 1.45 cm2 (0.65 to 3.8) for patients with
significant tumour at histology. Mean TZ area was 42.4 cm2
(10.0 to 68.9) for patients with benign histology; 33.9 cm2
(18.7 to 58.8) for patients with non-significant cancer, and
29.9 cm2 (9.3 to 61.2) for patients with significant cancer.
Mean proportion of TZ replaced by tumour was 5.3 % (range
1.7 to 14.0 %) for patients with significant tumour (Table 1).
Table 3 denotes the median values and interquartile ranges of
whole TZ MR textural parameters for patients with non-sig-
nificant/benign and for patients with significant tumour both
including and excluding the significant tumour. P-values de-
note the statistical significance of differences between whole
TZ for patients with non-significant/benign histology and pa-
tients with significant tumour for TZ ROIs (again including
and excluding the significant tumour). The ROC-AUC for
whole TZ textural parameters for each of the three MRI
Fig. 1 Demonstrates single slice
axial images of significant
tumours (arrow): (a) T2 weighted;
(b) ADC map; (c) pre-contrast T1
weighted; and (d) early post
contrast T1 weighted images in a
74-year-old patient with an
anterior right transition zone
tumour (Gleason 3 + 4; maximum
cancer core length 11 mm) prior
to transition zone contouring and
histogram analysis
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sequences, for classification of a TZ image as containing sig-
nificant tumour, are also detailed.
TZ textural metrics
All analyses were performed on a whole TZ basis (initially
incorporating significant tumour where present). Mean and
median TZ ADC were significantly higher (0.99 and 0.97 x
10-3 mm2/s, respectively, range 0.67 to 1.77) for patients with
non-significant/benign histology than those with significant
tumour (0.79 and 0.77 x 10-3 mm2/s respectively, range
0.07 to 1.22) (p = 0.004).
Kurtosis
Median ADC, T1 and T2 kurtosis were 0.09, -0.12 and 1.51,
respectively, for non-significant/benign histology versus -
0.51, -0.05 and 1.18, respectively, for TZ containing signifi-
cant tumour. Median ADC kurtosis was significantly lower
for patients with significant tumour (p < 0.001); whereas me-
dian T1 and T2 kurtosis were not significantly different be-
tween the groups (p = 0.96 and 0.78, respectively).
Entropy
Median ADC, T1 and T2 entropy were 5.90, 5.51 and 5.12,
respectively, for non-significant/benign histology and 5.67,
5.37 and 5.04, respectively, for TZ containing significant tu-
mour. Median ADC and T1 entropy were lower for patients
with significant tumour (p = 0.005 and 0.004, respectively)
whilst T2 entropy did not reach significance (p = 0.13).
Skewness
Median ADC, T1 and T2 skewness were -0.04, 0.16 and 0.60,
respectively, for non-significant/benign histology versus 0.00,
0.08 and 0.74, respectively, for TZ containing significant tu-
mours. There were no significant differences between the two
groups (p = 0.31 to 0.49).
Effect of excluding significant tumours on whole TZ
textural metrics
Following exclusion of significant tumours from the single-
slice whole TZ ROI, there was no longer a significant differ-
ence between median ADC value (p = 0.13), when patients
with those significant tumours were compared with those with
non-significant/benign histology.
Kurtosis
Following exclusion of significant tumours from the single-
slice whole TZ ROI, there was no longer a significant
difference between median ADC kurtosis, when patients with
significant tumours were compared with those with non-sig-
nificant/benign histology (p = 0.23). Median T1 and T2 kur-
tosis differences remained non-significant (p = 0.84 and 0.35,
respectively; Table 3).
Entropy
Significant differences between T1 and ADC entropy
remained, when patients with significant tumours and those
with non-significant/benign histology were compared follow-
ing exclusion of significant tumours from the former ROI (p
<0.01, Table 3).
Skewness
Median ADC, T1 and T2 skewness did not demonstrate any
consistent difference between patients with significant tu-
mours and those with non-significant/benign histology fol-
lowing exclusion of significant tumours from the TZ ROI.
Box-and-whiskers plot of the best performing textural pa-
rameters are illustrated in Fig. 2.
Disease classification by univariate textural metrics
The best performing classifier for ADC was kurtosis (0.80;
95 % CI 0.69 to 0.91). Entropy yielded the highest AUC for
early T1 post-contrast image (0.70; 95 % CI 0.57 to 0.84).
This analysis did not show significant differences on T2
weighted whole TZ textural analysis with the best performing
T2 parameter being T2 entropy (AUC of 0.61; 95%CI 0.47 to
0.75). LOO validation demonstrated ROC-AUC 0.78 (95 %
CI 0.66 to 0.90) for ADC kurtosis and 0.66 (95 % CI 0.52 to
0.80) for T1 entropy.
Disease classification by multivariate textural metrics
ROC-AUC for the best performing significant univariate pa-
rameters and bivariate combination of these parameters are
shown in Fig. 3. The two best performing parameters for
ADC (kurtosis) and T1 (entropy) combined in the bivariate
model gave ROC-AUC of 0.86 (95 % CI 0.77 to 0.95). LOO
analysis of this bivariate model yielded ROC-AUC 0.83
(95 % CI 0.74 to 0.93) and is shown in Fig. 4.
Discussion
This study evaluated the diagnostic accuracy of textural pa-
rameters, derived from clinical prostate mpMRI, for detection
of TZ cancer. Previous work has confirmed that quantitative
mpMRI parameters (e.g., ADC) can differ between benign
and cancerous TZ regions [18]. Unlike previous studies, here
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we derived single-slice whole TZ textural parameters (includ-
ing cancer pixels where cancer was present) and evaluated
differences in the histographic pixel distribution between pa-
tients with and without significant cancer.
We found that textural features from an image of the entire
TZ are altered significantly, when containing even a small
proportion of significant cancer, which no longer holds true
(for best performing textural parameter) when the same tu-
mour is excluded from the analysis. Overall, classification of
TZ tumour-containing slices by best performing single textur-
al parameter and/or bivariate combination (ROC-AUC 0.80 to
0.86) was comparable with previously reported visual
detection of TZ tumour by radiologists (ROC-AUC 0.73 to
0.84) [19, 20].
Kurtosis is a measure of histogram Bpeakedness^. Positive
kurtosis indicates a more peaked distribution of pixel signal
intensities. We found reduced ADC kurtosis was the best uni-
variate classifying textural feature (ROC-AUC 0.80 on ADC
images) on a whole TZ basis and demonstrated a higher ROC-
AUC than the non-textural parameter of ADC mean (ROC-
AUC 0.71 on ADC images). A larger cohort is required to test
the statistical significance of this difference. We expect textur-
al measures, based on the relationship of pixels in a given ROI
rather than absolute pixel intensities, are likely more robust to
Fig. 2 Box plots showing best
performing textural
discriminators of TZ ROIs
containing significance and non-
significance using ADC kurtosis
and early post-contrast T1. In
each box plot the box indicates
interquartile range; line indicates
median and whiskers indicate
most deviated data points/range.
Two tailed Mann Whitney U p-
values are also given for each
parameter
Fig. 3 Receiver operating
characteristic (ROC) curves of the
two best performing textural
features and bivariate
combination for discrimination of
transition zone ROIs containing
significant prostatic tumours from
non-significant TZ with area
under curve (AUC) values as
shown
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variations between individuals and scanners. Whilst kurtosis
measures from T2 and early post-contrast T1 weighted images
performed less well for the detection of cancer. In spite of the
relatively modest ratio of significant tumour compared to re-
maining TZ area (~5 %), we have found that exclusion of this
radiologically visible tumour from the single-slice whole TZ
ROI results in loss of significance in the difference in ADC
kurtosis between the two groups. We posit this to be the result
of elimination of a second differing signal intensity ‘popula-
tion’ (i.e., a low ADC significant tumour) from the TZ ROI
resulting in normalisation of kurtosis when compared to the
non-significant/benign cohort reflected in more ‘peaked’
values. Wibner et al. [21] have previously demonstrated the
utility of ADC-derived textural parameters in TZ tumour de-
tection and differentiating grade based on lesion analysis. The
textural analysis approach may obviate previously described
efforts to normalise by using ADC ratios (normalized to non-
tumorous tissues) [22], perform whole lesion measurement
and/or generate histogram analysis including median and
low percentile ADC values [23].
Entropy is a measure of image ‘busyness/irregularity’ and,
as such, the observation of significantly lower mean TZ en-
tropy values in patients with significant cancer would reflect
increased overall signal homogeneity. Post-contrast T1
weighted image entropy was the second best univariate clas-
sifier, in keeping with previously observed homogenous en-
hancement features of TZ tumours [20]. However, the obser-
vation that the significant difference in T1 entropy between
TZ containing significant tumours and non-significant/benign
TZ persists even after the exclusion of radiologically visible
tumours in the former group reflected more homogeneous
enhancement throughout the whole TZ in these cases. The
mechanism for this is unclear, though growing evidence
implicates chronic inflammation as a contributor to prostate
cancer development and progression [24] and present in be-
nign prostate tissue associated with high-grade prostate cancer
[25]. The finding of more homogenous enhancement in the
‘non-malignant’ parts of TZ harbouring significant tumours
may reflect these aspects of prostate cancer ontogeny. ADC
entropy was also significantly lower in single-slice TZ ROIs
containing tumours and this relationship persisted following
removal of cancer from the TZ ROI possibly due to the same/
similar mechanism. Additionally, at the time these data were
acquired, as demonstrated in Table 2, the lowest b-value used
for calculation of the ADC map was 0 sec/mm2, and it is
possible the findings of ADC entropy may at least in part
reflect a perfusion difference component. These findings
may not have been appreciated in prior quantitative imaging
studies, most of which concentrate on assessing the vascular
properties of tumours themselves, and further confirmatory
(histologically correlative) studies are required.
Several T2weighted features aid visual identification of TZ
tumours; including homogeneously reduced lesion signal in-
tensity, ill-defined lesion margins and lenticular lesion shape
[19]. However, on a whole TZ basis, the current study does
not confirm that quantitatively reduced whole TZ entropy (in-
creased homogeneity) on T2 weighted images is a particularly
good discriminator. This may relate to the relatively small area
of tumours compared with background non-tumorous TZ and/
or relate to the study size. Additionally, ADC and early post-
contrast T1 images reflect processes occurring on a ‘micro-
scopic’ level and can reflect field changes (for example, subtle
inflammatory change) that may explain the significance of
differences between benign TZ and that harbouring significant
tumours. Whilst several studies have described homogenous
reduced tumoral T2 signal compared to benign TZ, the
Fig. 4 Receiver operating
characteristic (ROC) curves of the
two best performing textural
features and bivariate
combination for discrimination of
TZ ROIs containing significant
prostatic tumours from non-
significant TZ ROIs after leave-
one-out (LOO) analysis with area
under curve (AUC) values as
shown
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remaining (and predominant approximately 95 % by area)
‘normal’ TZ glandular tissue is variably heterogeneous across
patients and images are more reflective of macroscopic differ-
ences and subtle changes in T2 signal induced by background
inflammation may be masked.
Skewness is a measure of histogram asymmetry; a zero
value indicates a symmetrical distribution around the mean.
Skewness was a relatively poor classifier of TZ cancer when
applied to any image sequence. It has been speculated [23]
that in prostate tumours densely packed with malignant cells,
the resulting histograms from tumour ROIs are likely to be
less skewed compared with tumours with more heterogeneous
cellular density. However, we evaluated skewness for all
pixels within the whole TZ, and the proportion of tumour
pixels may have been insufficient to influence skewness sig-
nificantly particularly given such variation in cellular density
is not captured by traditional histological grading [26].
To our knowledge, this study is distinct from other work as
it assessed in vivo textural features derived from each mpMRI
sequence for the entire TZ. The study was conducted as a
proof of concept for the purpose of detecting significant TZ
tumours. Future work will examine the translation of this con-
cept over whole TZ volume to examine utility in augmenting
visual radiologist assessment (e.g., added value of prompting
readers to areas for examination which may contain signifi-
cant cancer) and/or automated detection. Interpretation of im-
ages by radiologists is complex [27] and, although an assess-
ment of texture is made, to date this visual textural assessment
has not been characterised objectively. We believe that textur-
al analysis of each multiparametric image is analogous to the
manner by which radiologists visually localise TZ cancer on
mpMRI [4]. Other workers [e.g., 28, 29] have examined first
and second order (e.g., two-dimensional grey-level co-
occurrence matrix) textural features from one or more
mpMRI sequences from ROIs drawn around individual TZ
tumours. Such approaches, while informative, have less clin-
ical application, since they are more computationally intensive
and require the radiologist to first identify areas of concern.
Furthermore, where textural features of small lesions are eval-
uated at larger spatial scales, these features can be biased sig-
nificantly by region boundary. In contrast, assessment of the
entire TZ texture requires less development as a clinical diag-
nostic tool (i.e., only segmentation of the TZ from the PZ,
which may be an automated/semi-automated procedure [30])
and minimizes boundary-related effects.
Our study has some limitations. All mpMRI images were
acquired on a 1.5 T scanner and generalizability to 3 T plat-
forms was not assessed. However, our 1.5 T mpMRI protocol
was in keeping with recommendations from a European
Consensus meeting [31]. We did not use endorectal coils,
and note that the European Consensus Meeting failed to agree
regarding their necessity even at 1.5 T. We routinely perform
DCE MRI using a higher spatial resolution and lower
temporal resolution than some other centres as advocated by
recent guidelines [3, 32]. Therefore, we expect the generaliz-
ability of post-contrast T1 weighted textural feature findings
to be limited to centres that similarly maintain higher spatial
resolution. We did not have access to radical prostatectomy
specimens as a reference ground-truth. However, employment
of a TPM based reference standard [33], which is a significant
improvement over conventional TRUS biopsy [14], can help
avoid the spectrum bias towards more severe cases that occurs
with studies when prostatectomy specimens are mandated.We
acknowledge that there could be some error when registering
TPM histopathology to mpMRI. However, it should be noted
that prostatectomy specimens themselves are not free from
registration errors induced by processing (shrinkage,
distortion, and tissue-loss) [34]. Lastly, we manually
contoured the single-slice TZ ROIs though we do not expect
this to unduly affect the results and envisage automated seg-
mentation could be used as available.
Our results have immediate clinical relevance, and confirm
textural features may inform CAD software to highlight im-
ages on which significant tumours could be present within the
TZ. In developing this whole TZ approach using MRTA as an
imaging biomarker, it is recognised that a series of studies
would be required to further validate the findings as per var-
ious ‘roadmap’ approaches in contemporaneous guidelines
(http://www.cancerresearchuk.org/sites/default/files/imaging_
biomarker_roadmap_for_cancer_studies.pdf). This approach
could be adapted to several scenarios, subject to
demonstration of efficacy, for example, by drawing attention
to slice(s), which may require further examination for
radiologists, probability of significant tumours being present
across entire TZ and predictive information if there are
relevant ‘field’ changes across the TZ. The United Kingdom
NICE guidelines have adopted mpMRI for detection of
prostate cancer in patients with a negative non-targeted
TRUS biopsy (http://www.nice.org.uk/guidance/cg175
/chapter/recommendations). Our textural evaluation
technique may have particular relevance for such patients
who are more likely to have TZ tumours that are
systematically undersampled by TRUS [34].
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